1. |
SV, Kimchi-Sarfaty C, Sauna ZE, et al. P-glycoprotein: From genomics to mechanism. Oncogene 2003; 22: 7468-85.
|
2. |
RG, Cole SP. Function, evolution and structure of multidrug resistance protein (MRP). Semin Cancer Biol 1997; 8: 193-204.
|
3. |
D, List AF. Targeting the multidrug resistance-1 transporter in AML: Molecular regulation and therapeutic strategies. Blood 2004; 104: 1940-51.
|
4. |
W, Hendrikse NH, Elsinga PH, et al. P-glycoprotein activity and biological response. Toxicol Appl Pharmacol 2005; 207: 257-60.
|
5. |
AR, Glover CJ, Sewell JL, et al. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 1987; 262: 7884-8.
|
6. |
CL, Qian F, Wei DZ, et al. Induction of apoptosis in K562 human leukemia cells by 2', 4'-dihydroxy-6'- methoxy-3', 5'-dimethylchalcone. Leuk Res 2005; 29: 887-92.
|
7. |
C, Meoni C, Davalli AM. Fluorescent dyes for cell viability: An application on prefixed conditions. Histochem Cell Biol 2001; 115: 223-9.
|
8. |
DH, Wei HL, Zhao HS, et al. Arsenic trioxide overcomes apoptosis inhibition in K562/ADM cells by regulating vital components in apoptotic pathway. Pharmacol Res 2005; 52: 376-85.
|
9. |
P, List AF. Chemotherapy resistance in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001; 14: 211-33.
|
10 |
SY, Rhee YH, Jeong SJ, et al. Hydrocinchonine, cinchonine, and quinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/DX5 uterine sarcoma cells. Environ Toxicol 2011; 26: 424-31.
|
11 |
Y1, Akhmetova L, İşeri ÖD, et al. Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin- resistant MCF-7 cells. Cancer Chemother Pharmacol 2011; 67: 823-8.
|
12 |
JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59: 1391-9.
|
13 |
MA, Zhu QZ, El-Mahdy M, et al. Influence of p53 tumor suppressor protein on bias of DNA repair and apoptotic response in human cells. Carcinogenesis 1999; 20: 765-72.
|
14 |
S, Berger M, Goldberg Z, et al. Apoptosis—the p53 network. J Cell Sci 2003; 116: 4077-85.
|
15 |
V, Yu JY, Bleicher RJ, et al. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther 2004; 3: 633-9.
|
16 |
M, Nishimura C, Minamida M, et al. Pharma- cokinetic assessment of absorptive interaction of oral etoposide and morphine in rats. Bio Pharm Bull 2014; 37: 371-7.
|
17 |
G, Huang J, Xue K, et al. Enhanced intestinal absorption of etoposide by self-microemulsifying drug delivery systems: Roles of P-glycoprotein and cytochrome P450 3A inhibition. Eur J Pharm Sci 2013; 50: 429-39.
|
18 |
JS, Fan L, Wagenaar E, et al. P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharma- cokinetics of etoposide. Clin Cancer Res 2010; 16: 130-40.
|